Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000762396 | SCV000892709 | uncertain significance | not provided | 2018-08-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002360873 | SCV002660993 | uncertain significance | Cardiovascular phenotype | 2021-12-29 | criteria provided, single submitter | clinical testing | The p.R2157C variant (also known as c.6469C>T), located in coding exon 17 of the TNXB gene, results from a C to T substitution at nucleotide position 6469. The arginine at codon 2157 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005036091 | SCV005669507 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency; Vesicoureteral reflux 8 | 2024-01-30 | criteria provided, single submitter | clinical testing |